Sugi Predict

Sugi Predict / Compounds / SCHEMBL3756633

SCHEMBL3756633

SCHEMBL3756633

CC(C)(C)OC(=O)NC(C(=O)N1CCCC1)c1ccccc1-c1[c]nccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.35
▸ CTSK P43235 2/20 0.35
▸ CTSB P07858 1/20 0.35
▸ CTSS P25774 1/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ KLRK1 P26718 1/20 0.34
▸ MICA Q29983 1/20 0.34
▸ RAET1L Q5VY80 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ CALCRL Q16602 1/20 0.33
▸ MC4R P32245 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ DPP7 Q9UHL4 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3759224 0.98 CTSK (0.34) CTSLCTSKCTSBCTSSKMT2A
SCHEMBL4003839 0.83 ALDH1A1 (0.40) KMT2AL3MBTL1ALDH1A1HTTDPP4
SCHEMBL3760333 0.77 LMNA (0.36) CTSLKMT2AALDH1A1
SCHEMBL3761660 0.76 DPP7 (0.41) L3MBTL1ALDH1A1HTTDPP4DPP7
SCHEMBL20434046 0.74 CTSS (0.55) CTSLCTSKCTSSKMT2AKLRK1
SCHEMBL3759003 0.74 DPP7 (0.39) ALDH1A1HTTDPP4DPP7
SCHEMBL5443088 0.73 CTSS (0.54) CTSLCTSKCTSSKMT2AKLRK1
SCHEMBL5445090 0.73 CTSS (0.54) CTSLCTSKCTSSKMT2AKLRK1
SCHEMBL3751887 0.73 POLB (0.30) —
SCHEMBL3757391 0.73 CTSL (0.41) CTSLCTSKCTSBCTSSKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 — — EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 — — US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 — — EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA CTSL 4214/4885CTSK 1003/4885CTSB 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.